Cytek Biosciences, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Wen Bin Jiang
- Full Time Employees
- 700
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 47215 Lakeview Boulevard Fremont CA United States 94538-6407
- IPO Date
- Jul 23, 2021
- CIK
- 0001831915
- Website
- cytekbio.com
- Similar Companies
- Business
- Cytek Biosciences, Inc. (Nasdaq: CTKB) provides cell analysis solutions leveraging proprietary Full Spectrum Profiling (FSP) technology for high-resolution, high-content, high-sensitivity analysis in life sciences research, clinical diagnostics, immunology, oncology, and infectious diseases; core products include the Cytek Aurora and Aurora Evo flow cytometers, Cytek Aurora CS cell sorter, Northern Lights systems, Cytek NL-CLC, Cytek Orion reagent cocktail preparation system, Enhanced Small Particle (ESP) detection technology, Amnis ImageStreamX imaging flow cytometer, Guava easyCyte microcapillary flow cytometer, cFluor reagents, Tonbo Reagents, Thermo Fisher Scientific reagents, beads, buffers, solutions, SpectroFlo software, and Cytek Cloud platform; services encompass training, validation, and customer support. Founded in 1992 and headquartered in Fremont, California, the company serves academic institutions, pharmaceutical and biotech firms, contract research organizations, and diagnostic labs with global operations including expanded facilities in Europe such as a new Amsterdam site opened in December 2025 to enhance EMEA presence, customer service, and training capabilities. Recent developments feature the March 2025 launch of the affordable Cytek Muse Micro cell analyzer to broaden access for smaller labs and emerging markets, a December 2024 announcement of a $50 million stock repurchase program effective January 1, 2025 through December 31, 2025 succeeding the prior program, and reaffirmed 2025 revenue guidance of $196 million to $205 million as reported in November 2025.
Company News
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences Q3 Earnings Call Highlights
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Cytek Biosciences to Participate in Upcoming Investor Conferences
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month High – Here’s What Happened
1,315,332 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Bank of America Corp DE
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB
Cytek Biosciences to Participate in Upcoming Investor Conferences
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates